Apigenin, luteolin, and piplartine are core active components of Sugemule-4 that bind to EGFR, potentially treating insomnia through serotonergic synapse and calcium signaling pathways.

The Claim

Apigenin, luteolin, and piplartine are core active components of Sugemule-4 that bind to EGFR, potentially treating insomnia through serotonergic synapse and calcium signaling pathways.

This conclusion is most relevant to: Not applicable (in silico study using databases and computational models).

What the Research Shows

The conclusion draws on 1 linked study. Highlights from the cited literature:

• ▸Prediction of the therapeutic mechanism of Sugemule-4 in insomnia treatment using network pharmacology and molecular docking. (Medicine, 2025) —

How It Works

The proposed biological pathway:

• ▸Active compounds (apigenin, luteolin, piplartine) bind to EGFR with strong affinity
• ▸EGFR forms stable hydrogen bonds with these compounds
• ▸Modulation of serotonergic synapse and calcium signaling pathways
• ▸Multi-target, multi-pathway anti-insomnia effects

Who Might Benefit

Evidence fit by population:

• ▸Not applicable (in silico study using databases and computational models)

Recommended Dose

N/A

Limitations & Caveats

Important context when interpreting this evidence:

• ▸In silico predictions require experimental validation in vivo or in vitro
• ▸Limited to computational databases which may not capture all active compounds or targets
• ▸No human or animal subjects were directly tested

Frequently Asked Questions